Category: News

  • Deep-Tech Matrix

    Deep-Tech Matrix

    HTGF Deep-Tech Matrix: Navigating the Growth Path of Technology-Driven Startups

    Deep-tech companies develop technologies that can transform entire industries. That makes them exciting – especially for investors. Yet many startups struggle to clearly explain their potential.

    Often, what’s missing is a consistent and compelling story. HTGF experts Dr. Gernot Berger, Dr. Olaf Joeressen, and Yann Fiebig have tackled this challenge. In a recent paper, they outline what really matters for deep-tech startups – and present a practical tool to help: the HTGF Deep-Tech Matrix. 

    Deep tech stands for innovation rooted in science and engineering. Whether it’s AI, robotics, new materials, or biotech – deep-tech startups aren’t solving small, everyday problems. They tackle major societal and industrial challenges. The current momentum in deep tech is more than a trend. For many, it represents hope – hope that we can keep innovating at a high level. And for investors, it’s an opportunity to support radical change with the potential for significant returns. 

    The Deep-Tech Disconnect: why great tech alone is not enough to convince investors 

    Despite their promise, many deep-tech founders face a tough reality: investors hesitate. It’s not about quality or potential – it’s about a mismatch in expectations. This gap is called the deep-tech disconnect. It refers to the structural difference between how tech-heavy companies evolve and how most VC investors think. 

    Investment models of the past two decades have been shaped by software startups: fast Minimal Viable Products (MVPs), early user feedback, and low capital requirements. Deep tech doesn’t follow that path. These companies need years to develop, require substantial funding, and only reach market readiness much later. 

    That’s why deep-tech startups need a different kind of pitch – a well-crafted equity story. It has to go beyond standard slides and metrics. It must clearly define a big, unsolved customer problem. It must show why a scientific or technological breakthrough is the right – or only – way to solve it. And it must explain why this specific team is the one that can turn the idea into a product. A convincing story makes the technology tangible: with patents, deep expertise, and a realistic roadmap that connects lab to market. 

    The HTGF Deep-Tech Matrix: Navigating a Complex Journey 

    So how do you describe a startup’s progress if it’s not measured in revenue or MVPs? That’s where the HTGF Deep-Tech Matrix comes in. It’s a hands-on tool to plan, explain, and communicate the path from scientific idea to scalable business. It helps founders build a clear equity story – and creates a shared language between them and investors. 

    The matrix is based on two key dimensions: technology readiness and certainty for a huge market. Tech readiness is assessed using standard TRL scales – from early research (TRL 1–2) to proof-of-concept (3–4) to market-ready solutions (8–9). Successful founders know where they are, what comes next, and what they can already show. 

    The second dimension – the market – is often underestimated. But for fundraising, it’s crucial. Is the market proven? Is there strong growth potential? Is the problem clearly defined and validated by real customer demand? The matrix helps assess these questions, too. 

    Each cell in the matrix represents a unique combination of technology and market maturity. Ideally, a startup moves step by step to the top right corner – a scalable product in a large, validated market. Along the way, typical phases can be identified: from early concepts with no clear market (“No Money Land”) to Pre-Seed, Seed, Series A and B – where scalability and repeatable revenue come into focus. 

    Putting the Matrix to Work 

    An example from the field of engineering simulation illustrates how the matrix can be applied in practice. The company developed an early cloud-based prototype aimed at a previously underserved target group: engineers without access to traditional, high-cost CAD tools. While the technological feasibility was promising, the market potential had not yet been validated. The company’s development began at a medium technology readiness level and in a market environment that was still largely unexplored. 

    What proved decisive was a clearly defined go-to-market strategy, combined with systematic product management and increasing customer engagement. This allowed the company to make continuous progress toward scalability. A coherent and well-structured equity story – one that connected the customer problem, the unique technological approach, and the commercial roadmap – played a central role in gaining investor confidence and securing funding for further growth. 

    Conclusion: Building a Shared Understanding from Day One 

    The HTGF Deep-Tech Matrix is more than just an analysis tool – it’s a compass. It helps founders structure their story, define key milestones, and communicate their journey. It also creates mutual understanding between startups and investors – with shared expectations, clear language, and realistic planning. 

    For investors, the matrix provides clarity: what tech maturity and market development are realistic at each funding stage? It turns uncertainty into informed decisions. In short: the Deep-Tech Matrix brings structure to complex ventures – and lays the foundation for successful fundraising and sustainable growth. Because even the next deep-tech unicorn starts with a well-told story. 

    Discover the Framework Behind Successful Deep Tech Growth

    Whether you’re a founder, investor, or ecosystem stakeholder, the HTGF Deep-Tech-Matrix offers a clear, strategic model for planning and evaluating deep tech equity stories. Learn how to align technological maturity with market potential, identify critical value inflection points, and foster a shared understanding between startups and investors.

  • Stackgini pre-seed funding round

    Stackgini pre-seed funding round

    Stackgini emerges from stealth mode – with DAX 40 clients and the goal of revolutionizing IT decision-making.

    After a year of building product and traction in stealth, Stackgini today announces the closing of its pre-seed funding round in April 2024, backed by leading early-stage investors High-Tech Gründerfonds (HTGF) and xdeck Ventures, along with prominent business angels from the SaaS industry including Julius Göllner (ARRtist), Dr. Niklas Hellemann (SoSafe), Frank Piotraschke (SoSafe) und Lukas Gottschick (Pliant).

    As part of its public debut, Stackgini also reports strong demand, from both DAX 40 companies and several renowned enterprise clients such as Endress+Hauser, Grünenthal, Badenova, or Louis Motorrad, all of whom are already using the solution.

    Stackgini’s founding team (Photo: Stackgini)

    IT departments manage large IT portfolios (often over 1,000 solutions), while business units submit new requirements on a daily basis. Manually coordinating these demands across departments, systems, and siloed data not only slows down decision-making but also quickly leads to unnecessary licensing costs and increased complexity in the IT landscape. Stackgini offers an alternative: a data-driven platform that helps companies efficiently assess, select, and optimize their IT landscape.

    “We founded Stackgini to solve a problem every organization faces: fragmented, manual, slow IT decision-making,” says Johannes Bock, CEO and co-founder of Stackgini. “Our platform learns from existing IT stacks, contextualizes new IT demands, and proactively promotes the reuse of existing IT solutions — with the speed a modern IT requires.”

    The Intelligent Co-Worker for IT Departments

    Stackgini is on a mission to fundamentally modernize IT demand management. Since closing its pre-seed round in April 2024, Stackgini has been developing its SaaS platform in close collaboration with its customers. The product leverages proprietary AI to analyze internal portfolio data, IT requirements, and market data – delivering actionable IT solutions in real time. Stackgini acts as a co-worker across IT governance, enterprise architecture and IT procurement teams.

    Our product has already gained the trust of leading enterprises.

    Steven Waegenaer, Head of IT Governance and Strategy at Grünenthal Group, adds: “For us, Stackgini is a real game changer in demand management: we are able to work together with the business units at an early stage and in a data-driven manner and make well-founded decisions – thus preventing unnecessary costs and shadow IT.”

    Backed by Europe’s Leading Early-Stage Investors and experienced Business Angels

    The pre-seed round was led by High-Tech Gründerfonds (HTGF) and xdeck Ventures, with participation from experienced angels including Julius Göllner, Dr. Niklas Hellemann, Frank Piotraschke, and Lukas Gottschick.

    “We backed Stackgini because the team is taking a fresh, scalable approach to a universal enterprise pain point,” says Maurice Kügler, Senior Investment Manager at HTGF. “With rising IT complexity and talent shortages in IT architecture and procurement, fueling IT decision-making with AI is a huge opportunity.”

    Markus Gick, Managing Partner at xdeck Ventures, adds: “Stackgini has the vision, the team, and now the traction to redefine how enterprise IT decisions are made. We’re proud to support them on this journey.”

    The Road Ahead

    With growing enterprise adoption, Stackgini is now focused on expanding its engineering, customer success, and go-to-market teams. The company is further deepening integrations with existing governance, procurement, and enterprise architecture systems—working toward a world where IT decisions can happen in days, not months.

    “Our goal is simple: to become the AI-powered backbone of enterprise IT decision-making.” says Johannes.


    About Stackgini
    Stackgini is the AI-powered co-worker for IT decision-making and demand management in medium-sized and large enterprises. Our SaaS solution reduces the workload for IT teams, promotes the reuse of existing solutions, and automates compliance checks. It brings together all teams and tools – from IT service management and enterprise architecture to compliance and procurement. The platform enhances the internal IT knowledge of its customers with millions of market data points. With the help of our proprietary AI, companies gain deep insights into their IT portfolio for intelligent, data-driven IT decisions.

    Contact: Johannes Bock
    E-Mail: press@stackgini.de

    www.stackgini.de

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.   For more information, please visit HTGF.de or follow us on LinkedIn.    

    About xdeck Ventures
    xdeck ventures is an early-stage venture capital investor focusing on tech companies with superior solutions in process automation, applied big data / AI, and sustainability tech. xdeck ventures invests in inspiring teams with deep domain expertise and a distinctive understanding of the problem they are trying to solve. Moreover, they are looking for differentiated products or services that solve a real pain point for customers and teams who are building something significant with the spirit to walk the extra mile. As investor on eye level, xdeck ventures empower founders to constantly challenge their status quo by being their biggest critic and close sparring partner at the same time.

    www.xdeck.vc

  • Certivity raises €13.3M in Series A 

    Certivity raises €13.3M in Series A 

    Certivity raises €13.3M in Series A to shape the future of technical compliance 

    Certivity has raised €13.3 million in Series A funding.

    The Munich-based RegTech company is developing the first structured, AI-powered platform for managing technical compliance. The round was led by Almaz Capital and UVC Partners, with participation from existing investors Earlybird X, High-Tech Gründerfonds (HTGF), and Plug and Play. The fresh capital will be used to accelerate the go-to-market strategy, drive product development, and expand into new industries and international markets. 

    Certivity founders (Photo: Certivity)

    Founded in 2021 by Nico Waegerle, Bogdan Bereczki, Jörg Ulmer, and Sami Vaaraniemi, Certivity is tackling one of the most overlooked but critical problems in modern engineering: regulatory compliance. Engineers often spend 30–50 percent of their time navigating fragmented legal and regulatory documents to ensure products meet legal and regulatory standards. Mistakes lead to product recalls, safety failures, and billions in fines. Certivity is on a mission to change that.  

    The company offers a structured, AI-native SaaS platform that transforms complex regulatory documents into structured, machine-readable compliance intelligence, automating everything from requirement extraction to regulatory updates and the native integration into the engineering process. Certivity enables companies to build products faster while increasing the security to ensure compliance with all mandatory regulations. 

    “With this funding, we’re scaling our platform to become the category leader in technical compliance – starting in automotive and expanding into heavy machinery, consumer goods, defense, aerospace, and beyond,” says Nico Waegerle, CEO and Co-Founder of Certivity. “We’re broadening regulation coverage, enhancing AI, and deepening tool integrations. Thus, we are turning compliance from a mandatory requirement into a competitive advantage for our customers.” 

     “Certivity has fundamentally changed how we handle regulatory compliance. Our internal development processes have become significantly more efficient, eliminating substantial amounts of manual effort.” says Nicolas Maurin, Regulations & Standards Manager, Aptiv. 

    How the platform works: Turning regulatory complexity into structured knowledge 

    Certivity’s platform digitizes and structures regulatory content from over 50 jurisdictions using a proprietary ingestion pipeline and regulatory knowledge graph. This provides engineering and compliance teams with full traceability and real-time visibility into legal changes. 

    AI-driven modules consolidate amendments across different regulatory versions with high precision and classify, extract, generate, and test technical and regulatory requirements from unstructured legal texts. 

    Instead of managing compliance in disconnected documents or spreadsheets, teams can now organize interpretations, approvals, and legal references into product-specific compliance projects. With deep integrations into requirements management tools like Jama, Polarion, DOORS, and others, Certivity enables compliance to flow seamlessly into engineering workflows, creating a connected, auditable, and scalable process. 

    Laying the groundwork for industry-scale compliance 

    “Certivity is setting a new standard for how compliance is integrated into product development,” says Amanda Birkenholz, Principal at UVC Partners. “They solve a large and tedious problem for any company with regulatory requirements. Compliance challenges are no longer the exception – they are the norm. Instead of asking which products are subject to regulation, it’s nowadays more accurate to ask: which products aren’t?” 

    “With some of the largest and most innovative OEMs and Tier 1 suppliers as customers, Certivity has established itself as the leader in the automotive industry for regulatory compliance. With this funding the goal is to expand in two dimensions – 1) in addition to regulatory compliance, Certivity also wants to cover technical specifications and industry standards; and 2) enlarge footprint to a diverse set of industries such as heavy machinery, aerospace and defense and eventually medtech. We are very excited about this growth prospect” says Aniruddha Nazre, General Partner at Almaz Capital.  

    To support its customers at scale, the company is also investing in onboarding, training, and customer success while growing its team across engineering, product, and go-to-market functions. 


    About Certivity 
    Certivity is a RegTech company that transforms regulatory complexity into clarity and speed. By converting regulatory documents into structured, machine-readable compliance intelligence, we empower engineering and compliance teams to work more efficiently and seamlessly. Our platform uses large language models (LLMs) and domain-specific AI to generate “law as data” from global sources, enabling fully digital workflows. Certivity helps customers digitize and streamline their compliance processes, reduce costs, mitigate risks, improve collaboration, and accelerate product development. 
    More information on: https://www.certivity.io/  

    LinkedIn: https://www.linkedin.com/company/certivity  

    About Almaz Capital 
    Almaz Capital is a leading early-stage VC fund headquartered in Silicon Valley with offices also in Berlin. Almaz is investing out of its third fund and is backed by major institutional investors including the EIF, EBRD and Cisco. Almaz invests in enterprise software companies at seed and series A stages. Almaz has over 50 active portfolio companies and has had over 10 successful exits over the last 17 years. 

    Find out more at https://www.almazcapital.com 

    About UVC Partners 
    UVC Partners is a leading venture capital firm that invests in European B2B tech startups and has offices in Munich and Berlin. With more than €600 million in assets under management, the VC typically invests between €1 to €10 million initially and up to €30 million per startup in the areas of DeepTech, ClimateTech, Mobility, and Software/AI. As an independent partner of UnternehmerTUM, Europe’s leading startup hub, UVC Partners has unique access to proprietary deal flow, more than 1,000 corporates and SMEs, as well as to talents from the Technical University of Munich, which belongs to the best European technical universities. UVC Partners’ investment portfolio includes Flix, Isar Aerospace, planqc, Proxima Fusion, Reverion, Tacto, TWAICE, DeepDrive, STABL, and many more. All portfolio companies and founders benefit from the team’s extensive investment and exit experience, their ability to build sustainable category leaders, and the network of UnternehmerTUM enabling them to speed up market entry. 

    Learn more at www.uvcpartners.com

    About Earlybird 
    Founded in 1997, Earlybird identifies and backs exceptional early-stage companies on a pan-European basis – supporting them through their growth and development phases and providing financial resources, strategic support, plus access to an international network and capital markets. Through two separate strategies, Earlybird focuses on tech-enabled businesses in fintech/ insurtech, enterprise software, and deep tech (energy, food, and space) while Earlybird Health focuses on improving patient outcomes. Earlybird additionally has a Growth Opportunity Fund for follow-on investments, and a pro-bono impact initiative, Vision Lab. With EUR 2.5 billion under management across fund streams and a history of 9 IPOs and 35 trade sales, Earlybird is among Europe’s most established and active venture capital firms. 

    More information on www.earlybird.com, LinkedIn, and X.  

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits.

    HTGF has a fund volume of over 2 billion euros. Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.   

    For more information, please visit HTGF.de or follow us on LinkedIn

    About Plug and Play Tech Center 
    Plug and Play Tech Center is a leading innovation platform and one of the most active early-stage VC firms globally with multiple success stories and 30+ unicorns in the portfolio, including PayPal, Honey, N26 and Einride. Headquartered in Silicon Valley, Plug and Play invests across more than 20 industries. Their German offices are located in Stuttgart, Munich, and Hamburg, each focusing on collaboration between industry partners and startups in their respective fields — Mobility in Stuttgart, InsurTech, Brand & Retail in Munich, and Supply Chain & Logistics in Hamburg. 

    For more information, visit: https://www.plugandplaytechcenter.com/venture-capital  

  • Aegiq and Pixel Photonics partner

    Aegiq and Pixel Photonics partner to break through the current quantum computing performance ceiling and enable photonic quantum computing at scale

    Sheffield, UK – Aegiq, a leading photonic quantum computing company, and Pixel Photonics, a pioneering single-photon detection company, have signed a Memorandum of Understanding (MoU) to bring their technologies together on a shared photonic platform.

    The collaboration will combine Aegiq’s single-photon sources with Pixel Photonics’ waveguide-integrated superconducting nanowire detectors (WI-SNSPDs).

    This marks an important step towards building a scalable and practical quantum computing stack, where high-performance photon detection is key to making realworld quantum applications possible.

    Chip module (Photo: Pixel Photonics)

    Aegiq takes a modular approach to building a quantum computer offering customers a path to rapid scale and commercial usage. The company reliably creates photons on demand at GHz clock speeds, routes these through its processors, and finally detects and measures them – all in telecom wavelengths.

    Pixel Photonics’ single-photon detectors combine seamless photonic platform integration with exceptional performance and scalability. Their unique waveguideintegration approach offers the performance and scalability required for enabling advanced applications in quantum and beyond.

    “This collaboration combines Aegiq’s on-demand telecom photon sources with Pixel Photonics’ unique detector technology. By bringing these technologies together, we are unlocking quantum computing at scale.” said Scott Dufferwiel, CEO at Aegiq.

    “Pixel Photonics’ detectors are designed to seamlessly integrate with photonic platforms,” said Nicolai Walter, CEO at Pixel Photonics. “Our high-performance waveguide-integrated devices are highly scalable and align perfectly with Aegiq plans to deliver reliable photonic quantum computing at scale.”

    This partnership between Aegiq and Pixel Photonics is paving the way for transformative advancements in quantum technology, combining their expertise and innovation to overcome current challenges and unlock new possibilities for scalable, real-world quantum systems.


    About Aegiq
    Aegiq is a UK-based quantum computing company founded in 2019, built on over 20 years of research at the University of Sheffield. The company develops photonic quantum computers and quantum networking technologies, delivering scalable quantum solutions across multiple industries. It’s products include component modules, hardware systems, and software designed for reliable, on-premises deployment.

    For more information about Aegiq, visit aegiq.com

    About Pixel Photonics 
    Founded in 2021 as a spin-off from Münster University, Pixel Photonics GmbH specializes in high-performance single-photon detection technology. Its WI-SNSPDs combine scalability, ultra-fast detection rates, and high sensitivity, enabling transformative advancements in quantum computing, QKD, microscopy, and metrology. Since the launch of its detector series in 2022, Pixel Photonics has secured customers in research, quantum technologies, and life sciences. With an international team of over 35 employees, the company continues to push the boundaries of nanophotonics technology. Pixel Photonics is backed by funding from Quantonation and HTGF, and is part of several prestigious grants, including those from the German Federal Ministry of Education and Research (BMBF) and the European Innovation Council (EIC).

    For more information about Pixel Photonics, visit www.pixelphotonics.com.

    Press Contact
    Julia Kleine-Bley  
    julia.kleine@pixelphotonics.com

  • Sdui Group secures strategic Investment

    Sdui Group secures strategic Investment

    Sdui Group secures strategic Investment to accelerate its Mission to become the Operating System for European Schools

    Sdui Group, a leading European provider of cloud-based administrative software for K-12 schools, today announced a new growth investment led by Bain Capital’s Tech Opportunities fund, with participation from existing investors HV Capital and High-Tech Gründerfonds (HTGF).

    The funding will be used to strengthen Sdui Group’s product suite, deepen its support for educational institutions, and further its ambition to become the unified digital platform for education in Europe.

    Founded in 2018 in Germany, Sdui Group provides a fully integrated suite that supports schools across administrative needs from communication, attendance, scheduling, grading, and more. Today, Sdui Group serves thousands of institutions across Germany, Austria, Switzerland, and Spain, and is continuing to expand into new regions. Its modern, modular software is trusted by individual schools, districts, and governments to streamline operations. Sdui Group’s suite improves the experience for all stakeholders – teachers, students, administrators, and parents – and gives back valuable time to focus on teaching and learning.

    The Sdui Team (Photo: Sdui)

    As European school systems face rising complexity, increased digital expectations, and expanding public support and funding for education technology, institutions are looking for modern, reliable platforms that simplify their daily workflows. With a user-first approach and scalable, compliant cloud architecture, Sdui Group is well-positioned to lead this shift.

    “This is a moment of transformation for education in Europe,” said James Stevens, a Partner in Bain Capital’s Tech Opportunities business. “Sdui Group is emerging as a trusted and capable partner to help schools navigate that change. Daniel and his team have built a modern, intuitive platform that directly addresses the daily challenges of school administration. We’re excited to support their continued growth and impact across the region.”

    Sdui Group has already built strong momentum through both organic growth and acquisitions. The company has successfully integrated several regional software players, expanded its capabilities, and continues to invest in innovation, reliability, and user experience. “Bain Capital’s approach is unique – they combine strategic vision with real operational support,” said Daniel Zacharias, Founder and CEO of Sdui Group. “They’ve taken the time to truly understand our mission and the realities schools face every day. With their support – and the continued backing of HV and HTGF – we’re accelerating our work to build the digital backbone of European schools.”

    “We’ve been proud to back Daniel and Sdui Group since the early days and are thrilled to continue supporting this next phase of growth,” said Felix Klühr, Partner at HV Capital. “Bain Capital’s experience scaling software companies globally makes them a valuable addition to the partnership.”

    Markus Kreßmann, Partner at HTGF: “Sdui is systematically building its position as the No. 1 in the European EdTech market. This substantial round of financing will enable it to continue on this path. We are delighted to be part of this success story. When we invested in the seed round in 2019, we placed our trust in a founder who had only recently left school. Today, Sdui has grown to become one of Europe’s leading providers, employing over 230 people. It is a powerful example of what can be achieved when vision, entrepreneurial talent, and genuine demand come together.”

    Maurice Kügler, Senior Investment Manager at HTGF: “It’s been incredible to witness Daniel and the team’s journey since we initially partnered back in 2019. We’re thrilled to keep backing Sdui as they take the next big leap forward!”


    About Sdui Group
    Founded in Germany in 2018, the Sdui Group has developed into a leading provider of cloud-based software that enables digital communication and administration for schools and educational institutions across Europe. As a reliable partner, Sdui Group supports individual institutions, governments and ministries in their digitalisation effort, and develops innovative cloud-based solutions for schools and preschools.

    Sdui Group’s suite of tools supports messaging, attendance, scheduling, grading, and more-making everyday school workflows simpler, more secure, and more effective. The company is based in Koblenz, Germany and currently employs around 230 people based in several European countries.

    Questions or requests for additional information should be directed to: presse@sdui.de

    About Bain Capital
    Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on Linked!n and X (Twitter).

    Bain Capital’s Tech Opportunities business (www.baincapitaltechopportunities.com) aims to help growing technology companies reach their full potential. We focus on companies in large, growing end markets with innovative or disruptive technology where we believe we can support transformational growth. Our dedicated, tenured team has deep experience supporting growing technology businesses-bringing together differentiated backgrounds in private and public equity investing as well as technology operating roles. We invest behind fundamental long-term tailwinds as technology penetrates across industries, creating a large and growing number of investment opportunities.

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   

  • 10th Life Science Pitch Day at the IZB 

    10th Life Science Pitch Day at the IZB 

    10th Life Science Pitch Day at the IZB: Where Visionaries Meet Investors

    During the anniversary Pitch Day at the IZB, ten selected start-ups presented their groundbreaking ideas to a high-caliber panel of investors. 

    For the tenth time, the Innovation and Startup Center for Biotechnology (IZB), in cooperation with High-Tech Gründerfonds (HTGF), Bayer, Boehringer Ingelheim, and MEDICE hosted the Life Science Pitch Day – an established format that brings promising biotech start-ups together with leading investors and key decision-makers from the industry. 

    Investors and industry experts at Life Science Pitch Day 2025. Photos: Dominik Gierke / IZB.

    Christian Gnam, Managing Director of IZB, welcomed the guests and provided insights into the current developments at the start-up center. Together with co-organizers Dr. Achim Plum (Managing Director, HTGF), Ingo Klöckner (Head of Portfolio Strategy & Reporting, Leaps by Bayer), and Dr. Sebastian Kreuz (Executive Director, BI Venture Fund), he officially opened the event. Dr. Laura Pedroza (Senior Investment Manager, HTGF) guided the audience through the sessions. 

    During the event, ten selected start-ups presented their innovative approaches to solving urgent medical challenges. They took the opportunity to showcase their technologies and business models to more than 70 renowned investors and experts from the life sciences industry. 

    “With the 10th Life Science Pitch Day, we not only celebrated another milestone at IZB this year—alongside our 30th anniversary—but also demonstrated just how important Martinsried is as a hub for life sciences innovations. This event gives innovative start-ups a platform and direct access to leading investors. I would like to thank our long-standing partners for their continued support of this unique format,” commented Christian Gnam, Managing Director of IZB.  

    “The presentations at the Life Science Pitch Day were of outstanding quality. This is where scientific excellence converges with entrepreneurial drive – the fuel powering biotech innovation and a valuable resource for life science investors,” said Achim Plum, HTGF

    “Once again, the Life Science Pitch Day 2025 demonstrated the remarkable innovative strength of the sector. The technologies and ideas presented inspire optimism and spark curiosity about a new generation of medical breakthroughs,” said Sebastian Kreuz, Boehringer Ingelheim Venture Fund. 

    “A day full of inspiration: visionary founders, strong partners, insightful conversations, and excellent networking opportunities. Now in its tenth year, Pitch Day has firmly established itself as a must-attend event for the life science community,” explained Ingo Klöckner, Leaps by Bayer

    The following project teams presented their innovative research at the 10th Munich Life Science Pitch Day:  

    1. Toleris Biotherapeutics, Valentin Bruttel: Developing first-in-class biologics that leverage immune tolerance mechanisms from pregnancy to treat autoimmune diseases.  

    2. Tacalyx, Dr. Peter Sondermann: Developing innovative monoclonal antibody therapies for the treatment of cancer by targeting tumor-associated carbohydrate antigens (TACAs).  

    3. RN.AI Therapeutics, Dr. Justin S. Antony: Developing AI-supported, precise combination therapies for the treatment of inflammatory and immunological (I&I) diseases.  

    4. PHAME Therapeutics, Konstantin Hinnah: Utilizing a proprietary discovery engine to develop functional antibodies against GPCRs, a key target structure in chronic, high-burden diseases. 

    5. Dimericon Therapeutics, Ulrich Kessler: Developing precision therapies based on a peptide-based modality for targeting hard-to-drug, intrinsically disordered proteins. 

    6. Mighto Therapeutics, Dr. Hermann-J. Kaiser: Working on first-in-class small-molecule-based therapeutics for mitochondrial diseases such as MELAS, CPEO, and Parkinson’s disease.  

    7. Synendos Therapeutics, Andrea Chicca: Conducting clinical development of novel therapies for neuropsychiatric disorders such as PTSD through targeted modulation of the endocannabinoid system (ECS) using selective endocannabinoid reuptake inhibitors. 

    8. ARI-tx, Sebastian Hogl: Developing a first-in-class inhaled therapy for tissue regeneration in COPD-CB and other muco-obstructive lung diseases. 

    9. Dense Immune, Zahra Ghodratian: Developing a bioengineered dense-body-based immunotherapy for the prevention and treatment of HCMV in immunocompromised patients. 

    10. REVIER Therapeutics, Eva van Rooij and Matthias Dewenter: Developing novel therapies for HFpEF, a common heart failure condition, through targeted inhibition of class IIa HDAC activity.   


    About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich 
    The Fördergesellschaft IZB mbH, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. The IZB celebrated 30 years of promoting scientific and entrepreneurial innovation in May 2025. Currently, 26,000 m2 is home to more than 40 biotech companies and life science companies employing more than 700 people. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s, and various autoimmune diseases. A key criterion for the success of the IZB is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE, and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the companies. More information at www.izb-online.de/en/

    Press contact and photo material requests: 
    Marion Köhler, Head of Public Relations 
    Fördergesellschaft IZB mbH, Innovations- und Gründerzentrum Biotechnologie 
    Am Klopferspitz 19 
    D-82152 Planegg-Martinsried 
    Phone: +49 (0)89/55 279 48-17 
    E-Mail: koehler@izb-online.de 

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros.  
     
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.    
     
    Press contact  
    High-Tech Gründerfonds Management GmbH  
    Tobias Jacob, Senior Marketing & Communications Manager 
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de 

  • EvlaBio raises €21 million Seed Funding

    EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease.

    • EvlaBio secures €21 million Seed Funding to complete preclinical development and progress towards IND-enabling studies.
    • The financing round is led by Kurma Partners as well as AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF.
    • EvlaBio’s lead program consists of a first-in-class therapeutic monoclonal antibody treatment of left ventricular hypertrophy in the setting of chronic kidney disease with the potential to transform outcomes for millions of patients.

    EvlaBio, a life science startup pioneering innovative therapies for the treatment of Left Ventricular Hypertrophy (LVH) in the setting of Chronic Kidney Disease (CKD), announced today the successful closing of its seed funding round, one of the largest seed rounds closed in Germany to date. The financing will support the advancement of EvlaBio’s lead program, a first-in-class therapeutic monoclonal antibody targeting specifically the FGF23/FGFR4 signaling in the setting of CKD, one of the key drivers for LVH, which can lead to heart failure.

    Founded with a mission to address high unmet medical need in the cardiorenal field, EvlaBio is developing a targeted treatment for patients suffering from CKD with limited therapeutic options. The company’s lead asset is a novel monoclonal antibody designed to inhibit the pathological FGF23/ FGFR4 cardiac signaling axis — a critical driver of cardiac remodeling in patients with CKD.

    “Despite recent advances, the clinical need in LVH in the context of CKD remains significant, with high prevalence and substantial negative impact on patients’ outcomes. Even with improved management of hypertension and anemia, LVH often persists or even progresses in CKD patients”, said Wenzel von der Heydte, CEO & Co- Founder of EvlaBio. “EvlaBio’s approach is unique in its ability to directly target a key pathway on the cardiomyocyte level. This new therapeutic avenue has the potential to improve lives of millions of patients.”

    The program originates from Lead Discovery Center GmbH (LDC), a company established in 2008 by the technology transfer organization Max Planck Innovation, where it has been developed in collaboration with KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I).

    “Blocking cardiac FGF23/FGFR4 overdrive has the strong potential to become a very promising treatment option for millions of patients facing a high risk of cardiac remodeling and progression to heart failure in CKD,” said Thomas Kirmeier, COO & Co- Founder of EvlaBio. “Heart failure is a leading cause of morbidity and mortality in this patient population and our therapeutic approach offers a promising strategy to modify disease progression at its root.”

    The seed round was led by Kurma Partners, AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF, and will enable EvlaBio to complete preclinical development and progress towards IND-enabling studies.

    Hadrien Bouchez, Partner at Kurma Partners added: ”We’re excited to partner with EvlaBio as they advance their groundbreaking approach targeting the FGFR4/FGF23 pathway. The team’s deep scientific expertise and compelling preclinical data position them to address cardiac hypertrophy in CKD patients—a significant unmet medical need affecting millions worldwide. Their differentiated approach offers meaningful advantages over existing therapeutic options. This investment reflects our commitment to supporting innovative companies poised to transform patient outcomes in areas of high unmet need”.

    Clément Bertholet, Managing Partner at AdBio Partners added: ”This investment in EvlaBio, the first one for AdBio Partners in Germany, is driven by the key features of the product developed by the team to target the well-known FGFR4/FGF23 pathway. We are thrilled to support the company through its development to ultimately bring innovative treatments to patients in need”.

    Marek Kozlowski, Senior Investment Director at NRW.BANK, commented: “The FGFR4/FGF23 axis is a very well-validated target pathway, yet its clinical potential remains unrealized. EvlaBio’s research and development program can finally change this. With a substantial seed funding from NRW.Venture and this high-quality syndicate, EvlaBio is wellpositioned to advance the development of the lead candidate to the next value inflection point.“


    About EvlaBio
    EvlaBio is a life science company focused on developing first-in-class therapeutics for cardiovascular and cardiorenal diseases. Its lead program targets the FGFR4/FGF23 signaling axis, a critical driver of cardiac remodeling in chronic kidney disease. By advancing novel mechanisms grounded in strong translational science, EvlaBio aims to redefine treatment paradigms for CKD patients with high unmet medical need.  


    About Kurma Partners
    Kurma Partners is a key European player in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth capital, in particular through its funds Kurma Biofund I, II, III, IV, Kurma Growth, Kurma Diagnostics and Kurma Diagnostics 2, as well as the links the company has forged with a network of prestigious research institutes and hospitals. Kurma Partners was founded in July 2009 and is based in Paris and in Munich. Learn more at www.kurmapartners.com


    About AdBio Partners
    AdBio Partners is a European VC firm based in Paris and Barcelona that invests mainly in therapeutics-oriented projects. AdBio partners’ unique strategy combines early-stage investments in promising companies and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio Partners has made 28 European investments from two seed-funds. Those companies have raised more than €1Bn additional capital from international syndicates and strategics. Learn more at www.adbio.partners


    About Boehringer Ingelheim Venture Fund
    The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. With a commitment to revolutionizing the standard of care, the BIVF fosters long-term partnerships with scientists and entrepreneurs. The BIVF’s focus is on nurturing disease-modifying therapeutic concepts and facilitating their clinical application. The BIVF prioritizes the translation of first-in-class concepts that address significant medical needs in fields such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies. These innovative concepts often encompass novel platform technologies designed to tackle targets and diseases that were previously considered untreatable.
    With a fund volume of EUR 350 million, the BIVF operates as an evergreen fund, continually reinvesting to fuel its mission. The partners of the BIVF gain from the fund’s deep expertise in drug discovery & development, translational science, and management, along with access to a network of experts within the Boehringer Ingelheim organization. Currently, the BIVF supports a diverse portfolio of over 40 companies, leveraging its extensive experience to drive progress in healthcare.  

    For additional information, please visit boehringer-ingelheim-venture.com.


    About NRW.Venture (NRW.BANK)
    NRW.Venture is the venture capital fund of NRW.BANK, located in Düsseldorf. Together with private-sector investors, NRW.Venture invests up to 15 million euros of equity in young and innovative start-ups over several financing rounds, with NRW.BANK taking a minority stake with a term of three to seven years. But the Bank not only provides capital – an experienced team is the key to joint success. Since the inception of its venture capital fund in 2005, NRW.BANK has invested in over 30 companies within the life sciences and healthcare sectors, spanning biotech, medtech, diagnostics, lab tools, and digital health. The investment professionals at NRW.Venture bring many years of venture capital experience, often enhanced by backgrounds in technology and start-ups, leveraging their expertise and networks to maximise the success potential of start-ups.


    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   


    About LDC
    Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising earlystage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.  

    LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I and KHAN-II, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea Lead Discovery AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

    Further information at: www.lead-discovery.de
    Contact: pr@lead-discovery.de


    About KHAN-I
    KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with € 70 million under management. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I received an investment from the European Investment Fund (EIF) with the support of InnovFin Equity, and with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) under the Investment Plan for Europe.  KHAN-I is also supported by Austria Wirtschaftsservice GmbH Max Planck Foundation, and Thyssen’sche Handelsgesellschaft mbH. In addition, KHAN-I sustains a preferred partnership with the Max Planck Society (Max-Planck-Gesellschaft e.V.).

    Further information at: www.khanu.de

  • Carelane sets new standards for clinical research with AI-driven, end-to-end platform 

    Carelane sets new standards for clinical research with AI-driven, end-to-end platform 

    • Carelane increases speed and efficiency, and improves the quality of clinical trials with an AI-powered clinical research hub  
    • Significant time and cost savings: cost reduction of up to 80 percent  
    • Seed funding of EUR 2.6 million led by Vorwerk Ventures 

    As clinical studies are always increasing in complexity, research institutions’ software solutions remain fragmented and outdated. Carelane has developed an end-to-end platform that integrates all phases of a study, from protocol development to data analysis. Their innovative approach combines the latest AI technology with a structured digital protocol based on FHIR standards. More than 130 research sites across six continents already rely on Carelane’s software solution. “We’ve engineered a cutting-edge platform that meets the demands of intricate clinical studies and increases efficiency through AI and automation. Workflows are simplified, clinical trials can be completed faster, and the overall quality is elevated,” explains CEO Yannick Boerner

    The research tool of tomorrow 

    More efficient, cheaper, and higher-quality clinical trials – Carelane achieves this via:  

    • End-to-end platform: Carelane covers all steps from protocol development to evaluation, with seamless integration promoting efficient collaboration. This eliminates traditional bottlenecks by linking all stakeholders to a shared, real-time infrastructure.  
    • Resource efficiency: Because there are fewer manual processes, the burden on research sites is eased, leading to cost savings of up to 80 percent. And because of AI-driven assistance and automation, research teams save time on study setup, site onboarding and participant enrolment.  
    • Increased data quality: Standardized data collection, real-time monitoring with built in AI-agents, and automated validation ensure reliable data and reduce protocol amendments. 

    A new era for study planning and execution 

    Carelane supports research teams from the earliest planning phases. The platform’s integrated AI-agents assist in decision-making, planning, and automating complex processes. The structured digital protocol based on FHIR standards ensures improved data quality. It guarantees synchronization with downstream systems and enables source data capture through the ingestion of electronic health records (EHRs). Researchers and study teams can now seamlessly move from creating their digitized protocol to configuring and deploying integrated modules, including EDC, eConsent, eCOA, EHR/EMR integrations, tokenization, and participant management. 

    Future-proof research – collaborative and integrated 

    All stakeholders – from sponsors to CROs to research sites – should be able to collaborate in real-time – Carelane makes this a reality. Stakeholders can now manage processes more effectively, and eliminate people silos and data silos. The tool brings all stakeholders together in a single digital infrastructure for the first time. Instead of separate tools, users can now rely on just one platform for medical writing, clinical strategy, operations, and data management. Carelane’s collaborative platform revolutionizes clinical research – a vision that found broad support in the investor community. 

    Successful seed funding completed 

    After a successful pre-seed phase, Carelane secured 2.6 million euros in April 2025 during a seed funding round led by Vorwerk Ventures, with additional participation from High-Tech Gründerfonds (HTGF) and private investors. “Carelane is revolutionizing how clinical research is done. We are impressed by how quickly they have gained traction. This rapid adoption shows the value that their AI-driven, end-to-end platform brings to a sector which is hungry for more efficient and higher-quality research. We are excited to support the company in its course of growth,” says Sascha Günther, partner of Vorwerk Ventures. The capital will be used to expand sales and customer support, scale technological infrastructure, and drive the further development of AI functions. 


    About Carelane 
    Carelane is re-imagining how clinical research gets done – with AI-powered technology that breaks down both data silos and people silos. Carelane is the AI-native clinical-research hub combining protocol authoring, EDC, eCOA, eConsent, participant management, tokenization, data analysis, document management and EMR/EHR connectivity in a single collaborative workspace. Every stakeholder—Medical Writing, Clinical Strategy, Clinical Operations, Data Management, Regulatory, Market Access, Sites, CROs, Sponsors and participants—works from a single source of truth without bouncing between disconnected point solutions. 

    For more information: www.carelane.io 

    About HTGF – High-Tech Gründerfonds
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de

  • Biograil raises EUR 8.5 million to support clinical testing of oral therapeuticdelivery device

    Biograil raises EUR 8.5 million to support clinical testing of oral therapeuticdelivery device

    Biograil raises EUR 8.5 million to support clinical testing of oral therapeutic delivery device

    Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of therapeutics that would otherwise have to be injected, announced a first closing of EUR 8.5 million of a financing round led by Verve Ventures. Existing investors including HTGF and Megatrend participated. Acondis GmbH joined the syndicate as a new investor. Follow-up closings with additional funds are planned for later in 2025.

    Steffen Wagner, co-founder and co-CEO of Verve Ventures, will join Biograil’s Board of Directors. Wagner’s financial and investment expertise will be a valuable addition to the director group. The additional funds will support the preparation activities for the planned phase 1 clinical testing of BIONDD®.

    Biograil CEO Karsten Lindhardt said: “We are pleased to secure robust financing for Biograil by a strong syndicate of investors in a difficult financing landscape. Biograil has made great strides in advancing the BIONDD® technology, completing outstanding and extensive preclinical studies proving the oral delivery of many injectable compounds with comparable bioavailability to subcutaneous injections. Biograil looks forward to further developing the BIONDD® technology and completing the preparation for clinical studies bringing significant value to the platform.”

    Karsten Lindhardt, Biograil CEO (Photo: Biograil)

    Verve CEO, Steffen Wagner commented: “Verve Ventures is extremely happy to participate and lead this important Biograil financing. Biograil’s BIONDD® technology has matured significantly, is applicable to a broad range of opportunities and addresses a multi-billion-dollar market. I look forward to working closely with the Biograil team as Biograil moves to the next stage of development.”


    About Biograil ApS
    Biograil is a Copenhagen based biotech company developing pharmaceutical products based upon the BIONDD® device contained in a standard size, double zero or single zero, capsule able to deliver active therapeutics into the stomach mucosal wall to be effectively distributed in the human body. Such therapeutics can be currently marketed products, including multi-billion-dollar injectable pharmaceuticals or new chemical entities that cannot otherwise be delivered orally. The Biograil device uses a novel mechanism to facilitate the delivery of active substances, i.e., biologics, efficiently into the stomach wall utilizing a proprietary platform technology manufactured by injection molding. The team behind Biograil is a combination of seasoned entrepreneurs with extensive experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA.
    Biograil has collaborations with Eli Lilly & Co and CSL Behring. The Biograil investor syndicate includes Megatrend Invest, Verve Ventures, High-Tech Gründerfonds, Eli Lilly and Co., Sanner Ventures, Evonik Venture Capital, Acondis GmbH and Roquette Ventures.

    About Verve Ventures
    Verve Ventures is one of Europe’s most active venture capital firms, focusing on deep tech. Founded in 2010 in Switzerland, Verve backs outstanding startups based on scientific excellence from the Seed stage onward. It has an active portfolio of over 150 companies and has achieved over 20 successful exits. Through Verve Ventures, startups get access to an extensive network of sophisticated private and institutional investors who actively help them succeed.

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media Contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Steuerboard Secures €725K Pre-Seed Round

    Steuerboard Secures €725K Pre-Seed Round

    Steuerboard Secures €725K Pre-Seed Round to Revolutionize Tax Workflows with AI 

    Steuerboard, the Düsseldorf‑based B2B SaaS platform rethinking tax workflows, today announced it has raised €725,000 in a pre-seed financing round led by High‑Tech Gründerfonds (HTGF), with participation from SuperAngels Fund and serial entrepreneur Roland Fassauer.

    The funding will accelerate product development and deepen market expansion across Germany. 

    Jakob Brandt and Matyas Heins, founders of Steuerboard (Photo: Steuerboard)

    Tackling Tax Industry Bottlenecks with AI 
    Founded in July 2023 by Matyas Heins (29) and Jakob Brandt (28), Steuerboard tackles the specialist‑staff shortage in tax advisory firms by eliminating email “ping‑pong,” improving transparency and automating routine data processes. Its AI‑native platform integrates seamlessly with existing systems to deliver agentic AI to proactively handle routine decisions and workflows. 

    Tapping Into a €1.3B Opportunity in Germany’s Tax Tech Market 
    The global tax software market was valued at USD 18.5 billion in 2023 and is projected to grow at a 10 % CAGR through 2030 (source: marknteladvisors.com). In Europe, the tax management software segment alone generated USD 4.72 billion (€4.34 billion) in 2023 (source: Grand View Research). Germany is the largest national market—accounting for roughly 30 % of the European total—implying an annual opportunity of over €1.3 billion for solutions like Steuerboard. 

    “We’re thrilled to partner with HTGF and our angel investors to scale Steuerboard’s AI‑powered automations,” said Matyas Heins, Co‑Founder. “This investment will enable us to rapidly enhance features that save tax offices time and deliver a seamless, transparent experience for their clients.” 

    “Steuerboard’s AI‑first platform addresses a critical need in the tax advisory sector,” said Christian Arndt, Principal at HTGF. “We believe their centralized data approach will set a new standard for efficiency and collaboration.” 

    Rapid Adoption Fuels Ambitious Growth Roadmap 
    Since launch, Steuerboard has onboarded nearly 100 tax offices—ranging from boutique firms to larger practices with hundreds of employees—and supports thousands of businesses each month. Their rapid adoption underscores strong demand for digital, AI‑driven collaboration in Germany’s tax industry.  

     With the new capital, Steuerboard will expand its engineering and customer‑success teams, accelerate development of advanced agentic AI workflows, and broaden its sales footprint across the DACH region. Over the next 24 months, the company aims to redefine automation in the tax ecosystem by embedding intelligent, end‑to‑end workflows that anticipate advisor and client needs. 


    About Steuerboard 
    Founded in July 2023 and headquartered in Düsseldorf, Steuerboard is a B2B SaaS company on a mission to rethink tax workflows. Its AI‑native platform centralizes data, automates routine tasks, and provides transparent collaboration between tax advisors (“Steuerberater”) and their clients (“Mandanten”), helping firms overcome specialist‑staff shortages and boosting customer experience. 

    Press Contact: 
    pr@steuerboard.net 
    www.steuerboard.net 

    About superangels 
    Superangels is a business angel matching fund founded by experienced entrepreneurs Franzi Majer, Alexander Brand & Florian Gottschaller, sharing their passion for early-stage tech startups. What began as friends co-investing has grown into an early stage tech fund, investing with a curated network of expert business angels – the superangels. 

    Superangels matches investments in pre-seed and seed-stage startups across sectors like Climate Tech, AI, Deep Tech, and SaaS. By combining financial strength with deep industry insights, superangels enhances deal flow, strengthens startups, and improves outcomes for all stakeholders. 

    Driven by a belief in transformative entrepreneurship, superangels backs exceptional founders building the next generation of global tech champions. With already 75 investments in its portfolio, superangels is one the most active early stage funds in Europe. 

    Learn more at super-angels.eu or follow us on LinkedIn

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros. 

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121 
    t.jacob@htgf.de   

  • nuuEnergy Funding

    nuuEnergy Funding

    nuuEnergy Secures Multi-Million Euro Funding – and Aims to Rethink the Heat Pump Industry as a Premium Quality Provider 

    Heat pump installation and energy startup nuuEnergy has closed a seven-figure pre-seed funding round in spring 2025.

    Investors include HTGF, business angel club better ventures—with members such as energy entrepreneur Marco Vogt—alongside EnjoyVenture, Vireo Ventures, and Bynd. The funding will be used to launch and scale regional specialist craft businesses and to further digitalize the entire process from individual planning to installation and maintenance. 

    Unreliable installers, complex planning, opaque pricing—many Germans are still hesitant to switch to heat pumps. Digital providers often prioritize aggressive growth with a strong focus on sales, often at the expense of installation quality. Traditional craft businesses, on the other hand, frequently lack the capacity for in-depth consulting and planning. 

    This is where nuuEnergy comes in: Founded in 2023, the company combines the efficiency of digital processes with the quality and customer proximity of traditional craft businesses. 

    “Our customers want a local partner to guide them through the entire process – with top-notch quality in planning, installation, and service. That’s exactly what we offer through our regional businesses and digitalized planning,” says Tobias Klug, co-founder and CEO of nuuEnergy. 

    Photo: nuuEnergy

    The Better Way to Heat Pumps – Local, Digital, Human 

    nuuEnergy establishes its own regional craft businesses, fully integrated into the company. This allows nuuEnergy to merge the benefits of digital workflows – such as software-based planning and streamlined subsidy management—with the hands-on expertise and local presence of traditional tradespeople. A dedicated regional contact ensures smooth coordination and alignment throughout all stages. 

    “We’re the skilled trades’ answer to the big digital players who focus purely on sales and neglect quality,” says Julia Rafschneider, co-founder and CRO of nuuEnergy. “Our technicians are not just service providers – they’re the heart of our company. They are the experts, they plan, install, and deliver excellent craftsmanship. We provide the processes and technology to support them in doing just that.” 

    From initial consultation to final installation, all steps come from a single source. Tailored planning by skilled professionals ensures that every heat pump is precisely matched to its building. Proper sizing and high-quality installation reduce operating costs and extend the system’s lifespan. The Munich-based company has already successfully launched a second location in Hamburg, with a third site currently in planning. 

    A Growth Market with Enormous Potential 

    Demand for heat pumps is growing rapidly—despite a market dip in 2024. Following a record year in 2023, with over 350,000 installations in Germany (a 50% increase over 2022), the industry expects rising numbers again in 2025. By 2030, the German Heat Pump Association (BWP) forecasts up to 500,000 units installed annually to meet climate goals. The environmental impact is significant: switching to heat pumps can reduce a building’s CO₂ emissions by up to 70%. However, a shortage of skilled workers and inefficient processes are slowing progress. This is where nuuEnergy’s infrastructure comes in—to drive a new generation of the energy transition: locally rooted, digitally enabled, and human-centered. 

    For better ventures, this investment marks a key move in addressing one of the most critical levers in the energy transition. “Germany’s skilled trades sector holds the key to a successful heating transition—but a lack of skilled labor and inefficient processes are holding it back. nuuEnergy blends digitalization with excellent craftsmanship and offers a solution that doesn’t currently exist in the market—but is urgently needed,” says Tina Dreimann, founder and managing director of better ventures. 

    HTGF has been observing the heat pump market for some time and made a conscious decision to invest in the Munich-based startup: “Every house is different, and making renovations scalable is a challenge. We see nuuEnergy as the first convincing solution where a scalable model is emerging in close partnership with skilled trades—enabling millions of homes to switch to heat pumps without compromising quality,” says Johannes Weber, Principal at HTGF. 


    About nuuEnergy  
    Founded in 2023, nuuEnergy specializes in the planning and installation of heat pumps. With a unique business model, the company combines the advantages of digital processes with the quality and proximity of traditional craft businesses. The goal: to make the switch to climate-friendly heating as simple, efficient, and high-quality as possible. More at: www.nuuenergy.com 

    About better ventures  
    better ventures is Europe’s leading alliance for impact entrepreneurs. The network has invested in over 45 impact startups with more than 80 entrepreneurial angels and focuses on scalable business models that unite impact and returns. better ventures believes that entrepreneurs—founders, angels, and family business owners—are the most powerful lever to tackle the greatest challenges of our time. More at: www.betterventures.io 

    About EnjoyVenture 
    EnjoyVenture is one of Germany’s oldest venture capital firms, investing in early-stage technology and growth companies for over 25 years. More at: www.enjoyventure.vc  

    About Vireo Ventures 
    Vireo Ventures is a Berlin-based early-stage fund specializing in European startups in the energy and electrification sectors. More at: www.vireo.vc  

    About Bynd 
    Bynd is a leading Iberian startup fund that has been investing in disruptive European tech companies for 15 years. More at: www.bynd.vc  

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  

    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s 

    Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s 

    Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s 

    Europe’s fastest-growing fusion startup unlocks funding to advance commercial fusion technology and secure energy resilience for the continent. 

    Proxima Fusion, Europe’s fastest-growing fusion energy startup, today announced the close of a €130 million ($150 million) Series A funding round—marking it the largest private fusion investment round in Europe. 

    The Series A round was co-led by Cherry Ventures and Balderton Capital, with significant participation from UVC Partners, the DeepTech & Climate Fonds (DTCF), Plural, Leitmotif, Lightspeed, Bayern Kapital, HTGF, Club degli Investitori, OMNES Capital and Elaia Partners.  

    This brings Proxima Fusion’s total funding to more than €185 million ($200 million) in public and private capital, accelerating its mission to build the world’s first commercial fusion power plant based on a stellarator design.  

    Francesco Sciortino, CEO and Co-founder of Proxima Fusion, said: “Fusion has become a real, strategic opportunity to shift global energy dependence from natural resources to technological leadership. Proxima is perfectly positioned to harness that momentum by uniting a spectacular engineering and manufacturing team with world-leading research institutions, accelerating the path toward bringing the first European fusion power plant online in the next decade.” 

    Proxima Fusion Co-Founders (Photo: Proxima Fusion)

    Shifting global energy dependence  

    Proxima was founded in early 2023 as a spin-out from the Max Planck Institute for Plasma Physics (IPP), with which it continues to work closely together in a public-private partnership to lead Europe into a new era of clean energy. The EU, as well as national governments including Germany, the UK, France and Italy, are increasingly recognizing fusion as a strategic, generational technology essential for energy sovereignty, industrial competitiveness, and carbon-neutral economic growth.  

    By building on Europe’s long-standing public fusion investment and industrial supply chains, Proxima Fusion is laying the groundwork for a new high-tech energy industry—one that transforms the continent from a leader in fusion research to a global powerhouse in fusion deployment. 

    “We back founders solving humanity’s hardest problems — and few are bigger than clean, limitless energy,” said Filip Dames, Cherry Ventures Founding Partner. “Proxima Fusion combines Europe’s scientific edge with commercial ambition, turning world-class research into one of the most promising fusion ventures globally. This is deep tech at its best, and a bold signal that Europe can lead on the world stage.” 

    Proxima is taking a simulation-driven approach to engineering that leverages advanced computing and high-temperature superconducting (HTS) technology to build on the groundbreaking results of the IPP’s W7-X stellarator experiment. 

    Just earlier this year, together with the IPP, KIT and other partners, Proxima unveiled Stellaris. As the first commercial stellarator concept to integrate physics, engineering, and maintenance considerations from the outset, Stellaris has been widely recognized as a major breakthrough for the fusion industry, advancing the case for quasi-isodynamic (QI) stellarators as the most promising pathway to a commercial fusion power plant. 

    Daniel Waterhouse, Partner at Balderton Capital, said: “Stellarators aren’t just the most technologically viable approach to fusion energy—they’re the power plants of the future, capable of leading Europe into a new era of clean energy. Proxima has firmly secured its position as the leading European contender in the global race to commercial fusion. We are thrilled to partner with Proxima’s game-changing team of engineers, alongside Europe’s top manufacturers, to build a company that will be transformational for Europe.” 

    With this new funding, the company will complete its Stellarator Model Coil (SMC) in 2027, a major hardware demonstration that will de-risk HTS technology for stellarators and stimulate European HTS innovation. Proxima will also finalize a site for Alpha, its demo stellarator, for which it is in talks with several European governments already. Alpha is scheduled to begin operations in 2031, and will serve as the key step to demonstrate Q>1 (net energy gain) and move towards a first-of-a-kind fusion power plant . The company will continue to grow its 80+-strong team across its three offices: at the headquarters in Munich, at the Paul Scherrer Institute near Zurich (Switzerland), and at the Culham fusion campus near Oxford (UK). 

    “Fusion energy is entering a new era—moving from lab-based science to industrial-scale engineering,” said Dr. Francesco Sciortino. “This investment validates our approach and gives us the resources to deliver hardware that will be essential to make clean fusion power a reality.”  

    Ian Hogarth, Partner at Plural said: “Proxima Fusion exemplifies a new kind of European ambition – a full force effort to develop the world’s first fusion power plant. Since their first round of funding two years ago, Francesco and the team have hit extremely challenging milestones ahead of schedule and hired a team that spans plasma physics, advanced magnet design and simulation experts. Their peer-reviewed stellarator power plant design concept proves that fusion really can be commercially viable, and creates the opportunity for Europe to be first to the target.” 


    About Proxima Fusion 
    Proxima Fusion spun out of the Max Planck Institute for Plasma Physics (IPP) in 2023 to build the first generation of fusion power plants using QI-HTS stellarators. Proxima has since assembled a world-class team of engineers, scientists and operators from leading companies and institutions, such as the IPP, MIT, Harvard, SpaceX, Tesla, and McLaren. By taking a simulation-driven approach to engineering that leverages advanced computing and high-temperature superconductors to build on the groundbreaking results of the IPP’s W7-X stellarator, Proxima is leading Europe into a new era of clean energy, for good. 

    Media Contact: 
    Maria Dantz 
    Head of Communications 
    Proxima Fusion 
    Email: maria.dantz@gmail.com 
    Tel: +31 614715715 

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media Contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Mosanna Therapeutics Series A

    Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea 

    • Series A Funding to Advance MOS118 through Phase 2 Clinical Trials 
    • Biotech Veteran David Weber Appointed CEO to Drive Clinical Development 
    • Obstructive sleep apnea affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options 

    Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in Series A funding. The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body’s natural airway control. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures, and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF). 

    OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

    Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at bedtime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that, for reasons yet unknown, the natural airway reflex in OSA patients exhibits decreased activity during sleep resulting in loss of airway patency and apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting expansion of Mosanna’s pipeline. 

    Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors. 

    “What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue,” said Daniela Begolo, Ph.D., Managing Director with EQT Life Sciences. “MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.” 

    “With his deep expertise in biotech innovation and patient-centric therapies, Dr. Weber was the ideal choice to lead Mosanna into the next chapter,” said Jeni Lee, Ph.D., Partner with Pivotal bioVentures Partners. “We look forward to partnering with him and the Mosanna team to deliver on the promise of this life-changing sleep apnea treatment.” 

    “Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.” 

    With this funding, Drs. Begolo and Lee joined the Board of Directors alongside Dmitrij Hristodorov, Ph.D., General Partner at Forbion; Hewmun Lau, M.B.A., Principal at Broadview Ventures; and Tiba Aynechi, Ph.D., General Partner at Norwest. They join existing board directors Sascha Oliver Bucher, M.B.A., CEFA, co-founder and Partner at Forty51 Ventures; and veteran biotech CEO Ben Machielse, who also serves as board chair.  


    About Mosanna Therapeutics  
    Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. For more information, visit mosanna.com

    Media Contact 
    Jessica Flick 
    Cogenta Communications 
    jessica@cogentacom.com  

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • Medical Decision Alliance secures €3.3 million in seed funding

    Medical Decision Alliance secures €3.3 million in seed funding

    MDA – Medical Decision Alliance secures €3.3 million in seed funding to develop comprehensive surgical support systems 

    • Successful seed financing round led by High-Tech Gründerfonds (HTGF) with additional private investors and entrepreneurs  
    • Qualified MDA team systematically captures the experience and knowledge of the world’s leading surgeons and uses it to develop comprehensive and globally available assistance systems for the operating theatre.  
    • Already three partnerships with leading global medical technology companies to make surgical robots smarter. 

    Healthcare start-up MDA – Medical Decision Alliance has raised EUR 3.3 million in seed financing. The founding team, led by experienced life science entrepreneurs Dr Gunter Trojandt, Annett Christ and Daniel Bauer, has developed special software solutions that can be used to record the surgical techniques and decision-making routines of leading surgeons in detail and transfer them to AI-based assistance systems. 

    Making surgical robots smarter, pooling distributed knowledge. 

    Surgical robots and other specialised systems are increasingly being used in today’s surgery to improve the precision of procedures. However, individual decisions during surgery remain at the surgeon’s discretion and may be incorrect in some cases. Based on the decades of experience of renowned surgeons and in collaboration with leading manufacturers of robotic surgical systems, MDA is developing decision-making algorithms that suggest the most appropriate workflow for a wide range of patient situations.  

    In the future, surgical teams will be supported by intelligent algorithms as if the most experienced surgeon in the field were sitting right next to them. This will not only benefit the learning teams, but also the patients. 

    Making surgical knowledge available worldwide 

    A key priority is the education and training of the next generation of surgeons. MDA is committed to sharing expert knowledge through programmatic training solutions that are always up to date and available 24/7 – the digitalisation of surgical education. 

    “Together with MDA, we have digitised all key aspects of our surgical skills and developed an AI-based workflow engine called Virtual Proctor. Other clinics and doctors can now access it and benefit from our 20 years of experience – as far as I know there is no other system like it,” says Professor Markus Graefen, Medical Director of the Martini-Klinik at UKE GmbH, the Prostate Cancer Centre at the University Medical Centre Hamburg-Eppendorf. 

    MDA as a partner for innovative medical technology companies 

    In addition to robotics, which is the current focus of the MDA, the Virtual Proctor will also serve as a digital platform for interested MedTech partners to present their innovative products along specific indications. The focus will also be on the knowledge of experts who already use these products on a daily basis. This makes it easier for new customers to acquire additional expertise, as the Virtual Proctor provides conceptual knowledge, visual and clinically relevant content based on established standards and experience – real added value for clinics. 

    Dr Lena-Sophie Schütter, Investment Manager at HTGF, comments: “MDA’s well-coordinated team combines experience, expertise and a strong network – qualities that already characterised the success of their previous start-up. Through the structured development of a unique reference database, they are laying the foundation for AI-based training and decision-making algorithms. In this way, they are creating the conditions for greater safety, comparability and cross-clinic standards in robotic surgery – with the aim of providing better care for patients. ” 

    from left: Angela van Walsum-Koelewijn (Martini-Klinik), Daniel Bauer (MDA), Annett Christ (MDA), Dr. Gunter Trojandt (MDA), Prof. Dr. Alexander Haese (Martini-Klinik), Prof. Dr. Markus Graefen (Martini-Klinik) and Kathi Ehlert (Martini-Klinik) – Photo: MDA

    About MDA – Medical Decision Alliance 
    MDA was founded in 2023 by Dr Gunter Trojandt, Annett Christ and two business angels, Jozsef Bugovics and Nils Kröber. MDA has a total of 10 employees and is based in Leipzig, Germany. The founding team has been working together for more than 10 years and successfully sold their last joint company, SPI – Surgical Process Institute, to Johnson & Johnson – a leading global manufacturer of medical devices and surgical robots – in 2017. 

    The focus of SPI and MDA is on the operating room and improving the quality of patient outcomes. All developments are carried out in close collaboration with leading physicians, clinics and medical device companies.  

    With the capital from the current round of financing, MDA will double the size of its team, recruit additional clinics (knowledge providers) and medical device companies (collaborators), and develop AI-based surgical training and assistance solutions. 

    About HTGF – High-Tech Gründerfonds  
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 startups and achieved almost 200 successful exits.   

    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.   For more information, please visit HTGF.de or follow us on LinkedIn.    
     
    Media contact  
    High-Tech Gründerfonds Management GmbH  
    Tobias Jacob, Senior Marketing & Communications Manager   
    T.: +49 228 – 82300 – 121  
    t.jacob@htgf.de    

  • Jupus Seed

    Jupus Seed

    JUPUS Completes Successful Seed Round of €6.5 Million – Acton Capital as Lead Investor

    The Cologne-based Legal Tech startup JUPUS has raised €6.5 million in funding. The seed round was led by Acton Capital and existing investors such as HTGF (High-Tech Gründerfonds) and business angels.

    With this fresh capital, JUPUS plans to further develop its product, expand its market share, and shape the future of legal work. Already, hundreds of law firms are using JUPUS’s AI software to automate tasks through Artificial Intelligence.

    Team of JUPUS (Photo: JUPUS)

    AI Takes Over the Lawyer’s Daily Routine
    JUPUS offers the first fully automated AI solution for law firms that not only automates administrative tasks but also communicates directly with clients. JUPUS’s AI secretary is unique in the market: It enables law firms to manage their processes from the first call to the final legal document entirely through AI. Standard processes are not only digitized but fully automated. Hundreds of law firms in Germany are already successfully using the solution in their daily work. JUPUS addresses the industry’s most pressing challenge: the growing shortage of skilled workers.

    The Answer to the Industry’s Biggest Problem The increasing shortage of legal assistants is pushing law firms to their limits. Delayed response times, dissatisfied clients, and overwhelmed teams are the consequences. JUPUS addresses this issue by having AI take over time-consuming tasks, ignificantly relieving the law firm staff.

    Currently, law firms using JUPUS save an average of 40 work hours per month, and by 2026, this number is expected to increase to over 100 hours per month thanks to new AI functionalities. This allows law firms to better utilize their limited resources, increase client satisfaction, and remain operational despite the shortage of skilled workers. Tasks that once took hours are now completed in seconds with JUPUS, making efficiency the new standard in law firm operations.

    “We are at the beginning of a new era for the legal market,” says René Fergen, founder and CEO of JUPUS. “Artificial Intelligence will fundamentally change how legal work is organized and executed – with entirely new opportunities for law firms. With JUPUS, we are leading this transformation and enabling law firms to radically simplify and accelerate their workflows. Our goal is to mitigate the growing shortage of skilled workers and give law teams the freedom to focus again on what really matters: advising their clients.”

    JUPUS Automates What Law Firms Used to Need Entire Teams For
    Unlike previous solutions, JUPUS covers the entire process of law firm work – from the first client contact to the final legal document. The AI software communicates directly with clients, handles administrative tasks, coordinates appointments, and creates required documents. JUPUS is the first legal AI solution to fully integrate client communication, mandate preparation, and document drafting in one platform, fundamentally redefining law firm operations.

    New Funding to Expand the AI Solution in Law Firms Since its founding in 2022, the team, led by founders René Fergen and Jannis Gebauer, has already supported hundreds of law firms in Germany, helping them process their client requests with JUPUS. With this new funding, the company will continue developing its AI software and expand its market share.

    Acton Capital, one of Europe’s leading investors in digital business models, is confident in the vision and potential of JUPUS: “The legal market is undergoing a transformation, and JUPUS is ideally positioned to lead this change. The team has impressively shown how legal processes can be automated using AI – resulting in massive efficiency gains for law firms. We see JUPUS as having the potential to set a new standard in the legal world. We look forward to supporting the team on this journey,” explains Fritz Oidtmann, Managing Partner at Acton Capital.

    In addition to JUPUS, Acton Capital has supported well-known companies such as the leading e-commerce platform Etsy and the Canadian legal tech company Clio. JUPUS had previously raised €1.3 million in a pre-seed round from the High-Tech Gründerfonds and business angels such as Micha Grüber (Co-Founder 1KOMMA5) and Kilian Kaminski (Co-Founder Refurbed). With the current round of €6.5 million, this amount has now been quintupled, marking a significant step in the company’s expansion.

    About JUPUS
    JUPUS develops the first AI secretary specifically for law firms, enabling law teams to comprehensively automate their workflows. From the first call to the final legal document, JUPUS supports all central process steps fully through AI. Already, hundreds of law firms rely on JUPUS’s AI secretary.

    About Acton Capital
    Acton Capital is an international venture capital firm with offices in Munich and Vancouver. Since 1999, the team has been investing in technology-based business models from Europe and North America. With over two decades of experience and a deep understanding of digital transformation, Acton Capital has supported more than 100 startups, including global leaders such as Alphasights, Clio, HomeToGo, and Mambu. For more information, visit www.actoncapital.com.

    About HTGF – High-Tech Gründerfonds 
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact 
    High-Tech Gründerfonds Management GmbH 
    Tobias Jacob, Senior Marketing & Communications Manager  
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de   

  • HTGF backs Emerge Tech

    HTGF backs Emerge Tech

    HTGF backs Emerge Tech: AI Agents empower SMEs facing skilled worker shortage

    • HTGF invests in Emerge Tech, which uses AI agents to make employers more visible, improve the quality of applicants and reduce recruitment costs significantly.
    • Proof of impact: 40% better applicant matching, 87% cheaper than agencies and 54% less HR effort.
    • Seed round in preparation: Emerge is developing the leading AI platform for employer branding and people experience in medium-sized businesses.
    • Signal-sending founding team: combining tech innovation, HR vision and growth expertise, a Babbel co-founder, the founder of DEBA and an international scale-up architect are set to achieve new heights.

    High-Tech Gründerfonds (HTGF) and the Heimatboost investment community are investing in Emerge Tech GmbH, a Berlin-based HR tech start-up that uses AI-powered employer branding to put SMEs on an equal footing with large corporations by making the process more accessible, automated and effective. The investment will fund the development of the platform and prepare the seed round.

    “To solve the skills shortage, we must start with employers. Our AI agents will create game-changing opportunities, finally enabling smaller teams to stand out as employers and reshape HR.”

    Daniel Braun, Co-Founder & CEO, Emerge

    AI against the skills shortage: highly efficient and genuinely authentic.

    Although the shortage is not expected to peak until 2035, companies are already struggling to establish a presence in the labour market. Rather than relying on agencies, Emerge uses AI: Creative Carla defines your identity and message, while Channel Charly delivers them to the right channels based on data — precisely, measurably and scalably. What was once only available to large corporations with big budgets is now accessible to medium-sized companies too, with measurable success: a 40% better fit between people and organisation, 87% lower costs compared to agencies and 54% less effort in everyday recruitment. Thanks to AI, employer branding is no longer a one-off campaign, but an ongoing dialogue between companies and potential employees.

    “Employer branding has long been a privilege reserved for big brands. However, talent doesn’t make decisions based on budget; authenticity wins. That’s exactly where our AI comes in.”

    Reiner Kriegler, Co-Founder & CPO, Emerge

    Strategy & Outlook

    Until the end of 2025, Emerge’s focus will be on improving product quality and increasing user numbers with Carla and Charly, with the aim of creating a scalable, robust AI agent model. A seed round is planned for late 2025, after which the focus will shift towards internationalisation. At the same time, a new line of agents is being developed to support the entire people experience, from onboarding to performance management.

    “The complementary and experienced founding team at Emerge immediately impressed us. Their blend of HR expertise and technological know-how is precisely what is required to facilitate the long-term digital transformation of medium-sized businesses. We are delighted to support Emerge on this journey as an investor.”

    Christian Arndt, Principal at HTGF

    Founding team

    • Daniel Braun scaled the HR tech start-up WorkGenius to £150 million in revenue in the US and is now CEO of Emerge.
    • Wolf Reiner Kriegler: Employer branding pioneer and founder of the German Employer Branding Academy. Now CPO of Emerge.
    • Thomas Holl is the co-founder of the language learning app Babbel and is now the CTO of Emerge.

    With Emerge Tech, they are bringing technology to employers in need of real change.

    Founding team of Emerge Tech (Photo: Emerge Tech)


    About Emerge Tech

    Founded in Berlin in 2024, Emerge Tech GmbH develops specialised AI agents that digitise and enhance the employer attractiveness of small and medium-sized businesses faster, more efficiently and more affordably than any agency service. In 2025, the focus will be on user growth and product maturity, followed by international expansion in 2026 with new agents covering the entire people experience. Find out more about AI agents at emerge-tech.io.

    Media contact
    Emerge Tech GmbH
    Reiner Kriegler
    Co-Founder & CPO
    E-Mail: reiner@emerge-tech.io

    About HTGF – High-Tech Gründerfonds
    HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 startups and achieved almost 200 successful exits.  
    Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
    For more information, please visit HTGF.de or follow us on LinkedIn.   

    Media contact
    High-Tech Gründerfonds Management GmbH
    Tobias Jacob, Senior Marketing & Communications Manager
    T.: +49 228 – 82300 – 121
    t.jacob@htgf.de